Developer docs
API playgroundTry for free, no card

Search company profiles

Arima Genomics

Full company profile

uuid00038ld

Namestring
Arima Genomics
Legal namestring
Arima Genomics, Inc.
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Arima Genomics is a private biotechnology company founded in 2015 and headquartered in Carlsbad, California, that develops DNA-based cancer diagnostics built on a proprietary Hi-C sequencing platform capable of capturing the three-dimensional structure of the cancer genome from routine formalin-fixed paraffin-embedded (FFPE) tissue samples. Its commercial offering is the Aventa clinical testing brand, which comprises Aventa FusionPlus for solid tumors (launched 2023) and Aventa Lymphoma for B- and T-cell lymphomas (broadly launched September 2025), the latter reporting on 417 genes and granted AMA PLA code 0592U. The company operates a CLIA-certified clinical testing laboratory in Orlando, Florida, providing end-to-end specimen logistics with results typically returned in 10 business days, and sells research-use Hi-C kits globally through the Arima Discovery platform.

Arima serves three primary customer segments: oncologists and cancer centers requiring comprehensive genomic profiling for diagnosis and therapy selection; biopharma companies seeking biomarker-defined patient populations for targeted therapy development; and academic researchers studying 3D genome organization through collaborations that drive peer-reviewed publications in journals including Cell Genomics, Genes, and the Journal of Molecular Diagnostics. The company generates revenue through professional-services clinical testing fees, one-time research product licenses, and biopharma partnership arrangements, with no publicly disclosed pricing.

Recent evidence positions Aventa tests as superior to conventional FISH and RNA-seq for structural variant detection, including a 159-patient DLBCL study showing Hi-C detected 97% of clinically relevant biomarker rearrangements versus 76% for FISH, and a finding that Hi-C identified oncogene rearrangements in 37% of driver-negative NSCLC tumors. The company has raised approximately $29 million total in venture funding across a $7M Series B (March 2022) and a $22M Series C led by Illumina Ventures (June 2025), and is led by CEO Tom Willis, PhD, with founder Sid Selvaraj serving as President and COO. Notable institutional partnerships include Fox Chase Cancer Center — the first NCI-designated Comprehensive Cancer Center to implement Arima's technology as standard protocol — alongside multi-center studies with Johns Hopkins, Duke, University of Michigan, and NYU.

Short descriptiontext

Arima Genomics is a private cancer diagnostics company that uses proprietary Hi-C sequencing technology to detect gene fusions, rearrangements, and structural variants from FFPE samples, serving oncologists, biopharma, and academic researchers through its Aventa clinical tests and Arima Discovery research platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCarlsbad, United States
HQ citystring
Carlsbad
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
3D genome sequencing, cancer diagnostics, structural variant detection, clinical genomic testing, Hi-C sequencing technology
Industry3 codes
PRIMARYHLAGANAF
Epigenomics & Chromatin Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Cancer Genomics Diagnostics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Clinical Testing Services
TypeProfessional Services
Description

CLIA-certified laboratory providing Aventa clinical tests (Aventa FusionPlus for solid tumors and Aventa Lymphoma for lymphoma) to oncologists. Results typically returned in 10 business days with end-to-end specimen logistics.

arimagenomics.com
2Research Products
TypeOne Time License
Description

Advanced kits and informatics supporting discovery-stage researchers worldwide through the Arima Discovery platform.

arimagenomics.com
3Biopharma Partnerships
TypeProfessional Services
Description

Partnerships with biopharma teams to connect structural cancer drivers to therapeutic opportunity, identifying biomarker-defined patient populations and informing development strategy.

arimagenomics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1Aventa
Description

Clinical testing brand from Arima Genomics, bringing Hi-C sequencing technology into cancer care through tests designed for routine FFPE samples. Includes Aventa FusionPlus for solid tumors and Aventa Lymphoma for B- and T-cell lymphomas.

arimagenomics.com
+2 more records
Core offering1 text field

Arima Genomics develops and commercializes a proprietary Hi-C sequencing platform that captures the 3D structure of cancer genomes from routine FFPE tissue, operationalized through the Aventa clinical testing brand (Aventa FusionPlus for solid tumors and Aventa Lymphoma for B- and T-cell lymphomas) processed in a CLIA-certified lab. The company also distributes research-grade Hi-C kits and informatics via the Arima Discovery platform and runs biopharma partnerships that link structural cancer drivers to therapeutic and biomarker strategies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Hi-C detected 97% of clinically relevant biomarker rearrangements vs. 76% for standard FISH in DLBCL cohort of 159 patients
+3 more records
Product overview1 text field

Arima Genomics offers the Aventa clinical testing platform built on proprietary Hi-C sequencing technology. The platform consists of two clinical tests: Aventa FusionPlus for solid tumors and Aventa Lymphoma for B- and T-cell lymphomas. Both tests leverage genome-wide Hi-C sequencing to detect gene fusions, rearrangements, and structural variants from routine FFPE samples that conventional methods like FISH may miss or incompletely characterize. The platform powers clinical diagnostics, biopharma partnerships, and translational science research.

Product and service3 records
1Aventa FusionPlus
CategoryClinical cancer diagnostics
Description

Clinical test for solid tumors that detects clinically relevant fusions and rearrangements genome-wide using Hi-C sequencing from routine FFPE samples, supporting diagnosis and therapy selection for oncologists and cancer centers.

2Aventa Lymphoma
CategoryClinical cancer diagnostics
Description

First whole-genome NGS-based clinical test for gene fusion and rearrangement detection in B- and T-cell lymphomas, reporting on 417 genes from routine FFPE specimens; intended for oncologists and cancer centers for diagnosis, classification, prognosis, and treatment planning.

3Arima Discovery Research Kits
CategoryResearch genomics products
Description

Research-grade Hi-C kits and informatics sold through the Arima Discovery online storefront to discovery-stage researchers worldwide for studying 3D genome organization and cancer-driving structural mechanisms from FFPE samples.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-26
Description

Collaborated on Cell Genomics publication demonstrating FFPE-compatible Hi-C can identify clinically relevant rearrangements not captured by routine testing across 44 archival FFPE biopsies.

2New York University (NYU)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-26
Description

Collaborated on Cell Genomics publication demonstrating FFPE-compatible Hi-C can identify clinically relevant rearrangements not captured by routine testing across multiple lymphoid malignancies.

arimagenomics.com
3Fox Chase Cancer Center
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-08
Description

Partnership makes Fox Chase the first NCI-designated Comprehensive Cancer Center to implement clinical testing using Arima's 3D-genomics technology as part of standard protocol for multiple tumor types. The collaboration integrates clinical testing and research at scale, enabling new discoveries through analysis of de-identified patient response data for lymphoma and sarcoma diagnostics.

foxchase.org
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-04
Description

Multi-center study involving 159 DLBCL patients demonstrating Hi-C sequencing detected additional clinically relevant rearrangements that routine FISH panels missed, with superior performance for key biomarkers.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-15
Description

Collaborative study published in Genes journal showing Aventa Lymphoma test clarifies ambiguous FISH results and uncovers additional genetic rearrangements in B-cell lymphoma cases, demonstrating impact on diagnosis and treatment decisions.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Partnership to enable broad adoption of Arima Genomics' technology in clinical labs.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Partnership to facilitate clinician ordering of a 3D genomics-based lab-developed test for detection of gene fusions across cancer sample types.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical NGS lab offering NeXT Personal (tumor + immuno-oncology) with deep structural-variant and tumor-informed MRD capabilities. Closely comparable in size, clinical-cancer focus, and emphasis on detecting alterations missed by standard panels.

2Tempus Labs
TypeBroad incumbent
Description

AI-enabled precision medicine company offering NGS profiling (Tempus xT), liquid biopsy, and biopharma data services. Broader portfolio than Arima but directly competes for oncologist ordering, biopharma CDx deals, and payor contracts.

TypeBroad incumbent
Description

Roche-owned leader in comprehensive NGS-based cancer profiling (FoundationOne CDx/HDx). Direct competitor in clinical cancer genomics with established payer coverage, broad oncologist adoption, and FDA-approved CDx claims — but does not specialize in 3D-genome structural-variant detection like Arima.

TypeBroad incumbent
Description

Public clinical cancer genomics lab offering comprehensive solid-tumor and hematologic NGS panels (including Lymphoma Profile). Larger scale and broader menu than Arima but targets the same oncologist customer base with overlapping biomarker testing.

TypeDirect peer
Description

Hi-C and proximity-ligation genomics company focused on chromosome conformation and structural-variant detection for research and clinical applications. Closest pure technology peer to Arima, operating primarily in the research market with overlapping Hi-C platform approach.

TypeEmerging player
Description

Precision oncology company offering tumor profiling (Strata NGS) and clinical-trial matching for oncologists. Similar enterprise sales motion to cancer centers and biopharma, though narrower test menu and earlier commercial stage than Arima.

TypeDirect peer
Description

Optical genome mapping platform (Saphyr/Irys) for structural-variant detection in cancer and constitutional disorders. Direct technology competitor for structural-variant and rearrangement detection, though using imaging rather than Hi-C chemistry.

TypeDirect peer
Description

Operates a CLIA-certified lab offering MI Profile and other whole-transcriptome/whole-exome cancer tests targeting oncologists and biopharma. Closely comparable business model (CLIA lab + biopharma partnerships + clinical evidence-driven GTM) and competes for the same cancer-center customers as Arima.

TypeBroad incumbent
Description

Acquired by Agilent, offers ctDNA and NGS-based liquid-biopsy cancer profiling. Now part of Agilent's broader diagnostics portfolio; competes with Arima in liquid-biopsy-adjacent oncology applications and shares Agilent's investment history with Arima (Agilent co-invested in 2020 round).

10Pillar Biosciences
TypeEmerging player
Description

Clinical NGS panel developer offering targeted cancer profiling kits (including SLIMamp/PIK3CA panels) to clinical labs. Comparable in scale and clinical-cancer focus, though Arima is whole-genome/structural-variant while Pillar is targeted-panel.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Arima Genomics

Cancer Genomics Diagnosticsarimagenomics.com

Arima Genomics is a private cancer diagnostics company that uses proprietary Hi-C sequencing technology to detect gene fusions, rearrangements, and structural variants from FFPE samples, serving oncologists, biopharma, and academic researchers through its Aventa clinical tests and Arima Discovery research platform.

What Arima Genomics does

Arima Genomics is a private biotechnology company founded in 2015 and headquartered in Carlsbad, California, that develops DNA-based cancer diagnostics built on a proprietary Hi-C sequencing platform capable of capturing the three-dimensional structure of the cancer genome from routine formalin-fixed paraffin-embedded (FFPE) tissue samples. Its commercial offering is the Aventa clinical testing brand, which comprises Aventa FusionPlus for solid tumors (launched 2023) and Aventa Lymphoma for B- and T-cell lymphomas (broadly launched September 2025), the latter reporting on 417 genes and granted AMA PLA code 0592U. The company operates a CLIA-certified clinical testing laboratory in Orlando, Florida, providing end-to-end specimen logistics with results typically returned in 10 business days, and sells research-use Hi-C kits globally through the Arima Discovery platform.

Arima serves three primary customer segments: oncologists and cancer centers requiring comprehensive genomic profiling for diagnosis and therapy selection; biopharma companies seeking biomarker-defined patient populations for targeted therapy development; and academic researchers studying 3D genome organization through collaborations that drive peer-reviewed publications in journals including Cell Genomics, Genes, and the Journal of Molecular Diagnostics. The company generates revenue through professional-services clinical testing fees, one-time research product licenses, and biopharma partnership arrangements, with no publicly disclosed pricing.

Recent evidence positions Aventa tests as superior to conventional FISH and RNA-seq for structural variant detection, including a 159-patient DLBCL study showing Hi-C detected 97% of clinically relevant biomarker rearrangements versus 76% for FISH, and a finding that Hi-C identified oncogene rearrangements in 37% of driver-negative NSCLC tumors. The company has raised approximately $29 million total in venture funding across a $7M Series B (March 2022) and a $22M Series C led by Illumina Ventures (June 2025), and is led by CEO Tom Willis, PhD, with founder Sid Selvaraj serving as President and COO. Notable institutional partnerships include Fox Chase Cancer Center — the first NCI-designated Comprehensive Cancer Center to implement Arima's technology as standard protocol — alongside multi-center studies with Johns Hopkins, Duke, University of Michigan, and NYU.

Arima Genomics firmographics

Firmographics
Name
Arima Genomics
Legal name
Arima Genomics, Inc.
Website
https://arimagenomics.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Arima Genomics is a private cancer diagnostics company that uses proprietary Hi-C sequencing technology to detect gene fusions, rearrangements, and structural variants from FFPE samples, serving oncologists, biopharma, and academic researchers through its Aventa clinical tests and Arima Discovery research platform.
Ownership category
akta.pro rank

Arima Genomics industry classification

Industry
Product category
Cancer Genomics Diagnostics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGANAF
Epigenomics & Chromatin Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • 3D genome sequencing
  • Cancer diagnostics
  • Structural variant detection
  • Clinical genomic testing
  • Hi-C sequencing technology

Where Arima Genomics is headquartered

Location

Headquarters

HQ city
Carlsbad
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Arima Genomics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Clinical Testing Services: CLIA-certified laboratory providing Aventa clinical tests (Aventa FusionPlus for solid tumors and Aventa Lymphoma for lymphoma) to oncologists. Results typically returned in 10 business days with end-to-end specimen logistics.
  2. Research Products: Advanced kits and informatics supporting discovery-stage researchers worldwide through the Arima Discovery platform.
  3. Biopharma Partnerships: Partnerships with biopharma teams to connect structural cancer drivers to therapeutic opportunity, identifying biomarker-defined patient populations and informing development strategy.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Arima Genomics product offering

Product offering

Core offering

Arima Genomics develops and commercializes a proprietary Hi-C sequencing platform that captures the 3D structure of cancer genomes from routine FFPE tissue, operationalized through the Aventa clinical testing brand (Aventa FusionPlus for solid tumors and Aventa Lymphoma for B- and T-cell lymphomas) processed in a CLIA-certified lab. The company also distributes research-grade Hi-C kits and informatics via the Arima Discovery platform and runs biopharma partnerships that link structural cancer drivers to therapeutic and biomarker strategies.

Product overview

Arima Genomics offers the Aventa clinical testing platform built on proprietary Hi-C sequencing technology. The platform consists of two clinical tests: Aventa FusionPlus for solid tumors and Aventa Lymphoma for B- and T-cell lymphomas. Both tests leverage genome-wide Hi-C sequencing to detect gene fusions, rearrangements, and structural variants from routine FFPE samples that conventional methods like FISH may miss or incompletely characterize. The platform powers clinical diagnostics, biopharma partnerships, and translational science research.

Differentiator

Problem solved

Functional benefit

Brands

  • Aventa: Clinical testing brand from Arima Genomics, bringing Hi-C sequencing technology into cancer care through tests designed for routine FFPE samples. Includes Aventa FusionPlus for solid tumors and Aventa Lymphoma for B- and T-cell lymphomas.
  • Aventa FusionPlus
  • Aventa Lymphoma

Products and services

  • Aventa FusionPlus Clinical test for solid tumors that detects clinically relevant fusions and rearrangements genome-wide using Hi-C sequencing from routine FFPE samples, supporting diagnosis and therapy selection for oncologists and cancer centers.
  • Aventa Lymphoma First whole-genome NGS-based clinical test for gene fusion and rearrangement detection in B- and T-cell lymphomas, reporting on 417 genes from routine FFPE specimens; intended for oncologists and cancer centers for diagnosis, classification, prognosis, and treatment planning.
  • Arima Discovery Research Kits Research-grade Hi-C kits and informatics sold through the Arima Discovery online storefront to discovery-stage researchers worldwide for studying 3D genome organization and cancer-driving structural mechanisms from FFPE samples.

Quantifiable outcome

  • Hi-C detected 97% of clinically relevant biomarker rearrangements vs. 76% for standard FISH in DLBCL cohort of 159 patients
  • +3 more outcomes

Companies that use Arima Genomics

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Arima Genomics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Arima Genomics partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • University of MichigancoreStrategic or Co-development Partner · 26 February 2026Collaborated on Cell Genomics publication demonstrating FFPE-compatible Hi-C can identify clinically relevant rearrangements not captured by routine testing across 44 archival FFPE biopsies.
  • New York University (NYU)coreStrategic or Co-development Partner · 26 February 2026Collaborated on Cell Genomics publication demonstrating FFPE-compatible Hi-C can identify clinically relevant rearrangements not captured by routine testing across multiple lymphoid malignancies.
  • Fox Chase Cancer CentercoreStrategic or Co-development Partner · 8 January 2026Partnership makes Fox Chase the first NCI-designated Comprehensive Cancer Center to implement clinical testing using Arima's 3D-genomics technology as part of standard protocol for multiple tumor types. The collaboration integrates clinical testing and research at scale, enabling new discoveries through analysis of de-identified patient response data for lymphoma and sarcoma diagnostics.
  • Duke UniversitycoreStrategic or Co-development Partner · 4 December 2025Multi-center study involving 159 DLBCL patients demonstrating Hi-C sequencing detected additional clinically relevant rearrangements that routine FISH panels missed, with superior performance for key biomarkers.
  • Johns Hopkins UniversitycoreStrategic or Co-development Partner · 15 October 2025Collaborative study published in Genes journal showing Aventa Lymphoma test clarifies ambiguous FISH results and uncovers additional genetic rearrangements in B-cell lymphoma cases, demonstrating impact on diagnosis and treatment decisions.
  • VelseraminorChannel Partner/ Reseller/ DistributorPartnership to enable broad adoption of Arima Genomics' technology in clinical labs.
  • Protean BiodiagnosticsminorChannel Partner/ Reseller/ DistributorPartnership to facilitate clinician ordering of a 3D genomics-based lab-developed test for detection of gene fusions across cancer sample types.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Arima Genomics competitors and assessment

Company assessment

Direct peers

  • Personalis: Clinical NGS lab offering NeXT Personal (tumor + immuno-oncology) with deep structural-variant and tumor-informed MRD capabilities. Closely comparable in size, clinical-cancer focus, and emphasis on detecting alterations missed by standard panels.
  • Phase Genomics: Hi-C and proximity-ligation genomics company focused on chromosome conformation and structural-variant detection for research and clinical applications. Closest pure technology peer to Arima, operating primarily in the research market with overlapping Hi-C platform approach.
  • Bionano Genomics: Optical genome mapping platform (Saphyr/Irys) for structural-variant detection in cancer and constitutional disorders. Direct technology competitor for structural-variant and rearrangement detection, though using imaging rather than Hi-C chemistry.
  • Caris Life Sciences: Operates a CLIA-certified lab offering MI Profile and other whole-transcriptome/whole-exome cancer tests targeting oncologists and biopharma. Closely comparable business model (CLIA lab + biopharma partnerships + clinical evidence-driven GTM) and competes for the same cancer-center customers as Arima.

Broad incumbents

  • Tempus Labs: AI-enabled precision medicine company offering NGS profiling (Tempus xT), liquid biopsy, and biopharma data services. Broader portfolio than Arima but directly competes for oncologist ordering, biopharma CDx deals, and payor contracts.
  • Foundation Medicine: Roche-owned leader in comprehensive NGS-based cancer profiling (FoundationOne CDx/HDx). Direct competitor in clinical cancer genomics with established payer coverage, broad oncologist adoption, and FDA-approved CDx claims — but does not specialize in 3D-genome structural-variant detection like Arima.
  • NeoGenomics: Public clinical cancer genomics lab offering comprehensive solid-tumor and hematologic NGS panels (including Lymphoma Profile). Larger scale and broader menu than Arima but targets the same oncologist customer base with overlapping biomarker testing.
  • Resolution Bioscience (Agilent): Acquired by Agilent, offers ctDNA and NGS-based liquid-biopsy cancer profiling. Now part of Agilent's broader diagnostics portfolio; competes with Arima in liquid-biopsy-adjacent oncology applications and shares Agilent's investment history with Arima (Agilent co-invested in 2020 round).

Emerging players

  • Strata Oncology: Precision oncology company offering tumor profiling (Strata NGS) and clinical-trial matching for oncologists. Similar enterprise sales motion to cancer centers and biopharma, though narrower test menu and earlier commercial stage than Arima.
  • Pillar Biosciences: Clinical NGS panel developer offering targeted cancer profiling kits (including SLIMamp/PIK3CA panels) to clinical labs. Comparable in scale and clinical-cancer focus, though Arima is whole-genome/structural-variant while Pillar is targeted-panel.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Arima Genomics social profiles

Digital presence

Arima Genomics compliance and trust

Trust signal

Compliance1 record

Arima Genomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Arima Genomics leadership team

Management profile

Number of profiles

Profiles8 records

Arima Genomics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Arima Genomics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arima Genomics

What does Arima Genomics do?

Arima Genomics develops and commercializes a proprietary Hi-C sequencing platform that captures the 3D structure of cancer genomes from routine FFPE tissue, operationalized through the Aventa clinical testing brand (Aventa FusionPlus for solid tumors and Aventa Lymphoma for B- and T-cell lymphomas) processed in a CLIA-certified lab. The company also distributes research-grade Hi-C kits and informatics via the Arima Discovery platform and runs biopharma partnerships that link structural cancer drivers to therapeutic and biomarker strategies.

Is Arima Genomics a public or private company?

Arima Genomics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Arima Genomics founded?

Arima Genomics was founded in 2015. It employs 11 to 50 people.

Where is Arima Genomics based?

Arima Genomics is headquartered in Carlsbad, United States, in the North America region.

How does Arima Genomics make money?

Three revenue lines are on record. Clinical Testing Services are the primary driver. The others are research Products and biopharma Partnerships.

Who are Arima Genomics's main competitors?

Direct peers on record are Personalis, Phase Genomics, Bionano Genomics and Caris Life Sciences. Broad incumbents are Tempus Labs, Foundation Medicine, NeoGenomics and Resolution Bioscience (Agilent). Emerging players are Strata Oncology and Pillar Biosciences.

Does Arima Genomics have an API?

No public API is recorded for Arima Genomics.

What industry is Arima Genomics in?

Arima Genomics's product category is Cancer Genomics Diagnostics. Its primary akta.pro industry code is HLAGANAF, Epigenomics & Chromatin Profiling Services, with a secondary code of HLAAAMAJ, Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics). Its NAICS code is 541714 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SdbnActive Motif Announces Exclusive Global Distribution Agreement with Arima Genomics for Advanced 3D Genomics Solutions – San Diego Biotechnology NetworkActive Motif announced an exclusive global distribution agreement with Arima Genomics to offer advanced 3D genomics solutions to researchers. The agreement expands Active Motif's research genomics portfolio while supporting Arima's strategic focus on its clinical diagnostics platform called CARLSBAD. The partnership was announced on July 6, 2026, from Carlsbad, California.PR NewswireActive Motif annonce la signature d'un accord exclusif de distribution mondiale avec Arima Genomics pour des solutions génomiques 3D de pointeActive Motif and Arima Genomics have signed an exclusive worldwide distribution agreement, making Active Motif the sole global distributor of Arima's research Hi-C products and services. Under the agreement, Arima will concentrate on advancing its clinical diagnostic platform Aventa, which focuses on cancer detection using combined sequencing and DNA structure analysis. The partnership leverages Arima's 3D genomics technology leadership with Active Motif's established global commercial network and technical support capabilities, providing broader access to Hi-C technology for academic, pharmaceutical, biotech, and clinical research organizations.PR NewswireActive Motif gibt eine exklusive weltweite Vertriebsvereinbarung mit Arima Genomics für fortschrittliche 3D-Genomik-Lösungen bekanntActive Motif, a provider of epigenetics and multiomics solutions, announced an exclusive worldwide distribution agreement with Arima Genomics, a cancer diagnostics company specializing in 3D genomics and Hi-C sequencing technology. Under the agreement, Active Motif becomes the exclusive global distributor for Arima's Hi-C products and services for research applications, while Arima will concentrate on its clinical diagnostics platform "Aventa." The partnership aims to expand access to 3D genomics technologies across research, pharmaceutical, biotechnology, and clinical research institutions.AijournActive Motif Announces Exclusive Global Distribution Agreement with Arima Genomics for Advanced 3D Genomics SolutionsActive Motif announced an exclusive global commercial distribution agreement with Arima Genomics, making Active Motif the exclusive worldwide distributor of Arima's Hi-C products and services for research applications. The agreement allows Arima to sharpen its focus on its Aventa clinical diagnostics platform while expanding Active Motif's portfolio with 3D genome mapping technologies. The partnership combines Arima's technology leadership in 3D genomics with Active Motif's global commercial infrastructure and scientific expertise, with immediate effect.PR NewswireActive Motif Announces Exclusive Global Distribution Agreement with Arima Genomics for Advanced 3D Genomics SolutionsActive Motif announced an exclusive global commercial distribution agreement with Arima Genomics, making Active Motif the exclusive worldwide distributor of Arima's Hi-C products and services for research applications. The agreement enables Arima to sharpen its focus on its Aventa clinical diagnostics platform while expanding Active Motif's portfolio of epigenetics and multiomic solutions. The partnership combines Arima's 3D genomic technology leadership with Active Motif's global commercial infrastructure, with the agreement effective immediately.PR NewswireActive Motif Announces Exclusive Global Distribution Agreement with Arima Genomics for Advanced 3D Genomics SolutionsActive Motif announced an exclusive global commercial distribution agreement with Arima Genomics, making Active Motif the exclusive worldwide distributor of Arima's Hi-C products and services for research applications. The partnership allows Arima to concentrate on its Aventa clinical diagnostics platform while expanding Active Motif's multiomics portfolio to include 3D genome mapping technologies. The agreement is effective immediately, combining Arima's 3D genomics technology with Active Motif's global commercial infrastructure.MorningstarActive Motif Announces Exclusive Global Distribution Agreement with Arima Genomics for Advanced 3D Genomics SolutionsActive Motif announced an exclusive global distribution agreement with Arima Genomics for Arima's Hi-C products and research services. The deal allows Active Motif to distribute Arima's 3D genomics technology while Arima focuses on its Aventa clinical diagnostics platform. The agreement is effective immediately.Business Wire BlogArima Genomics Announces Distribution Partnership with Active Motif for Research-Specific Hi-C Sequencing Kits and ServicesArima Genomics announced a distribution partnership with Active Motif for its research-specific Hi-C sequencing kits and services, which aim to support genomics research applications. This partnership is part of Arima's strategy to concentrate on its clinical diagnostic platform for cancer, which uses Hi-C technology to detect structural genome alterations in cancer samples.FinancialContent Business PageArima Genomics Announces Distribution Partnership with Active Motif for Research-Specific Hi-C Sequencing Kits and ServicesArima Genomics announced a distribution partnership with Active Motif, granting exclusive distribution rights to Arima’s Hi-C kits and services for research applications covering cell lines, blood, and fresh-frozen tissues. The agreement allows Arima to sharpen its strategic focus on its core clinical diagnostic platform, which includes the Aventa FusionPlus and Aventa Lymphoma tests for solid tumors and lymphoma. Malek Faham of Illumina Ventures noted that the partnership positions Arima to address important limitations of conventional cancer testing and deliver insights for patient care.BioSpaceArima Genomics to Present Data at AMP Europe Showing Hi-C Sequencing Outperforms High-Coverage Whole Genome Sequencing for Lymphoma Rearrangement DetectionArima Genomics announced new data presented at the AMP 2026 Europe Congress demonstrating that its Hi-C sequencing-based Aventa™ Lymphoma test detects clinically relevant rearrangements missed by high-coverage whole genome sequencing. The study found that WGS pipelines identified only 51% to 71% of variants detected by Hi-C, with significant misses in key lymphoma-associated genes like MYC and BCL2. These findings support Hi-C sequencing as a superior method for comprehensive detection of diagnostic and prognostic biomarkers in routine lymphoma biopsies.